Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
about
Single vs. combination immunotherapeutic strategies for glioma.New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016Novel immunotherapy clinical trials in malignant pleural mesothelioma.Immunotherapy for malignant pleural mesothelioma: current status and future directions.Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Targeted therapy for soft tissue sarcomas in adolescents and young adults.Chimeric antigen receptor T-cell therapies for lymphoma.T cell optimization for the treatment of pancreatic cancer.Novel Immunotherapies for Multiple Myeloma.The importance for immunoregulation for long-term cancer control.An Update on the Use of Immunotherapy in the Treatment of Lymphoma.Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Is autoimmunity the Achilles' heel of cancer immunotherapy?Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.Adoptive T-Cell Therapy for Solid Tumors.Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.CAR T-cell therapy of solid tumors.Is immunotherapy here to stay in multiple myeloma?Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Development of CAR T cells designed to improve antitumor efficacy and safety.CAR T-cell therapy for pancreatic cancer.Modeling Natural Killer Cell Targeted Immunotherapies.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelIncreasing the safety and efficacy of chimeric antigen receptor T cell therapy.CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.Transcriptional and epigenetic regulation of T cell hyporesponsiveness.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Therapeutic T cell engineering.Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.Driving an improved CAR for cancer immunotherapy.CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.Next frontiers in CAR T-cell therapy.Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.
P2860
Q33746041-3A3C7D56-1F62-4F86-A958-DE0C496DBDC9Q33814908-A0AA010B-1D35-4749-9B1F-8DD1DD2ADFECQ33871577-0A0355ED-5122-42AB-9611-29B8E7FE21E2Q33890551-2D58E908-3BF6-4FE3-9BC6-123DFB471579Q37587362-A9FF9D90-FEB6-42F9-954B-3053492641B0Q37728639-4D89D735-89B1-4337-BC7F-CE233A9D7CA9Q37742014-FF44F02F-37A1-4797-8D0E-7D5E401E0E82Q38600697-68D2EC20-9719-464B-9D75-D099C8E455C0Q38638035-72B70FB7-3A2C-47A9-A3FA-859DEE60B1B5Q38640444-E32A4D0F-2763-4302-B66A-94C270C9EDF2Q38647002-2B7CD12C-D086-4340-8590-09407AE422A2Q38666304-CD1A4742-3E88-42E9-8B0A-7093B2323DCAQ38685785-D586BD68-673A-44C0-96BE-EA49711C2E2DQ38687375-943A3092-3E4D-464F-8F5F-D8291DF6A3C1Q38747333-185C5AC0-ED95-4B85-8AB6-2815043B0A0DQ38754498-96240645-F763-4D8D-AFDE-C136E101825FQ38874911-64DAA532-3A47-4B28-A17B-AE7301E4E9BAQ39007364-D9FFDF74-B2C9-436D-AAC2-B6C402D2C711Q39039017-73FA79AC-2990-4A61-BAE8-D7C545EB65AAQ39047856-2706E41A-5357-4492-BE51-E22CD014454DQ39084427-6815BBAB-681E-4E75-918B-6B828D907B19Q39194733-78C4D204-5CB0-436C-8DA0-DD24027DD112Q39200527-491BC5C1-2FF2-4583-9CB0-3165B48DA6BCQ39202440-55955F84-2034-47FA-9755-90BFBA249B59Q39239278-D60C77A6-9BD3-4A1A-9FFA-492B714CDBA5Q39246685-227C1E82-20F0-45BF-BDB6-CE26CD32502FQ39249589-797E1448-C4E3-4FBE-A7B9-A7F93909F7D2Q39256918-8BCD0CDC-4AF1-4884-A4AE-733C3A495AADQ39305346-2D97311E-65C4-466F-8ABD-1FE094192A75Q39367810-98D3934D-EBF7-40FC-8D88-CEB26467E38CQ40095245-67B3F6BC-2C8F-439C-8132-100720E461FEQ40199809-4C903BD5-DDED-4910-B8D0-FB6D5AB562EDQ41033228-361BBF99-50D5-40A4-A8C3-FD41629485E0Q41844141-AD7F7327-9BE3-49FE-99CF-08D9619477B2Q45868734-97AEE5D4-3A59-4E6C-9375-40CA97B64FB7Q45870945-7EDEEEFE-497F-44DF-8945-91FF3FE6BEF5Q46082373-4CE13084-2FF2-4A01-9843-6EE6DB90AA0AQ46694980-3AE16399-0B92-43D9-B22E-2DFFE3FCA774Q46848787-44ACB43C-BA88-451C-A9CB-C9B16581BB46Q47094171-D7969BE0-D58B-4B8B-9CE0-66045B613BE8
P2860
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human CAR T cells with cell-in ...... ist tumor-mediated inhibition.
@en
Human CAR T cells with cell-in ...... ist tumor-mediated inhibition.
@nl
type
label
Human CAR T cells with cell-in ...... ist tumor-mediated inhibition.
@en
Human CAR T cells with cell-in ...... ist tumor-mediated inhibition.
@nl
prefLabel
Human CAR T cells with cell-in ...... ist tumor-mediated inhibition.
@en
Human CAR T cells with cell-in ...... ist tumor-mediated inhibition.
@nl
P2093
P2860
P356
P1476
Human CAR T cells with cell-in ...... ist tumor-mediated inhibition.
@en
P2093
Aurore Morello
David R Jones
Dimiter S Dimitrov
Jonathan Villena-Vargas
Leonid Cherkassky
Michel Sadelain
Prasad S Adusumilli
P2860
P304
P356
10.1172/JCI83092
P407
P577
2016-07-25T00:00:00Z